Serial No.: 10/088,632 Group Art Unit No.: 1648

## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## We Claim:

Claims 1-25 (Cancelled).

- 26. (Currently amended) A monovalent influenza vaccine composition comprising an influenza virus component that is a low dose of egg-derived, purified, whole influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak, or has the potential to be associated with a pandemic outbreak, in combination with a suitable adjuvant, wherein the low antigen dose is less than 15 µg of haemagglutinin per dose, and wherein the adjuvant is at least one aluminium salt.
  - 27. (Cancelled).
  - 28. (Cancelled).
- 29. (Previously presented) The vaccine composition according to claim 26, wherein the adjuvant is a mixture of aluminium hydroxide and aluminium phosphate.
- 30. (Previously presented) The vaccine composition according to claim 29, wherein the amount of aluminium phosphate exceeds the amount of aluminium hydroxide.
- 31. (Previously presented) The vaccine composition according to claim 26, wherein the aluminium salts are present in the range of from about 0.4 to about 1.0 mg per vaccine dose.
- 32. (Previously presented) The vaccine composition according to claim 26, wherein the low antigen dose is less than 10  $\mu$ g of haemagglutinin per dose.
- 33. (Previously presented) The vaccine composition according to claim 32, wherein the antigen dose is between 0.1  $\mu g$  and 7.5  $\mu g$  or between 1 and 5  $\mu g$  of haemagglutinin per dose.

Serial No.: 10/088,632 Group Art Unit No.: 1648

- 34. (Previously presented) The vaccine composition according to claim 26, wherein the influenza virus antigen is substantially free of host cell contamination.
- 35. (Previously presented) The vaccine composition according to claim 26, wherein the influenza virus component is purified by a method that includes a protease incubation step to digest non-influenza virus proteins.

36-40. (Cancelled).

41. (Currently amended) A method for the production of an influenza vaccine for a pandemic situation, said method comprising admixing egg-derived, purified, whole influenza virus antigen from a single influenza virus strain that is associated with a pandemic outbreak or has the potential to be associated with a pandemic outbreak, with a suitable adjuvant, wherein the adjuvant is at least one aluminium salt, and providing vaccines lots that contain less than 10 µg influenza haemagglutinin antigen per dose.

42-43. (Cancelled).

- 44. (Previously presented) The vaccine composition of claim 26, wherein the antigen is selected from an H2 antigen and an H5 antigen.
  - 45. (Cancelled).
- 46. (Previously presented) The method of claim 41, wherein the antigen is selected from an H2 antigen and an H5 antigen.

47-50. (Cancelled).

51. (Currently amended) A method for treating a patient with a monovalent influenza vaccine composition, said method comprising the step of administering to the patient an influenza virus component that is a low dose of egg-derived, purified, whole influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak, or has the potential to be associated with a pandemic outbreak, in combination with a suitable adjuvant, wherein the low antigen dose is less than 15 µg of haemagglutinin per

Serial No.: 10/088,632 Group Art Unit No.: 1648

dose or no more than 15  $\mu$ g per administered dose of vaccine, and wherein the adjuvant is at least one aluminium salt.

- 52. (Previously presented) The method according to claim 51, wherein there is more than one separate administered dose, the total of which is less than 15  $\mu$ g of haemagglutinin or no more than 15  $\mu$ g of vaccine.
- 53. (Previously presented) The vaccine composition according to claim 26, wherein the adjuvant is chosen from the group of: aluminium hydroxide and aluminium phosphate.
- 54. (Previously presented) The vaccine composition according to claim 44, wherein the H2 antigen is H2N2, and the H5 antigen is H5N1.
- 55. (Previously presented) The method according to claim 46, wherein the H2 antigen is H2N2, and the H5 antigen is H5N1.
- 56. (Currently amended) A kit comprising a monovalent influenza vaccine composition, wherein said composition comprises an influenza virus component that is a low dose of less than 15 µg of haemagglutinin per dose, of egg-derived, purified, whole dose influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak, or has the potential to be associated with a pandemic outbreak, in combination with a suitable adjuvant, wherein said kit contains less than 10 µg influenza haemagglutinin antigen per administered dose, and wherein the adjuvant is at least one aluminium salt.